aβ-in-1 tfa

Aβ-IN-1 TFA inhibits and reverses different types of protein aggregation.

Pam3CSK4 TFA (Pam3Cys-Ser-(Lys)4 TFA) is an agonist of toll-like receptor 1/2 (TLR1/2) (EC50 of 0.47 ng/mL for human TLR1/2).

JAG-1, scrambled TFA is a scrambled sequence of JAG-1(188-204).

pro-asp TFA(85227-98-1 free base) (TLβ4) down-regulate skin inflammation in mouse skin.

Nociceptin (1-13), amide is a potent agonist Opioid receptor-like1 (ORL1) receptor with a pEC50 of 7.9 for mouse vas deferens and a Ki of 0.75 nM for binding to rat forebrain membranes.

Angiotensin 1/2 (1-9)TFA is containing the amino acids 1-9 that are converted from Angiotensin I/II peptide.

TT2-32 TFA induces a biphasic activation of phosphotyrosine phosphatase activity in human colon tumor cell line, SW620

Jagged-1 (188-204) TFA(219127-21-6 free base) is a fragment of the JAG-1 protein. JAG-1 is Notch ligand, a peptide that is the most conspicuously expressed ligand in skin. JAG-1 induces epidermal maturation. Exposing submerged keratinocytes monolayers to JAG-1 with elevated calcium concentration produces stratification with loricrin expression and NF-alphaB activation.

Rotigaptide TFA(355151-12-1 free base) is a novel and specific modulator of Cx43 and is a potent AAP. Rotigaptide TFA(355151-12-1 free base) prevents the uncoupling of Cx43-mediated gap junction communication and normalizes cell-to-cell communication during acute metabolic stress.

AZD 1775 Linker Conjugate 1 TFA is a compound involved in ubiquitinase-targeted chimeric assays

740 Y-P(TFA)(1236188-16-1 free base) (740YPDGFR(TFA)) is a potent and cell-permeable activator of PI3K.

IRL-1620 (TFA) is a potent selective endothelin receptor B (ETB) agonist with a Ki value of 16pm.

Apelin-13 is an endogenous ligand of APJ receptor, and the EC 50 value of activated G protein coupled receptor is 0.37 nM.

GLP-1 (1-36) amide (human, rat) TFA, a molecular variant of GLP-1 (7-36) amide, can induce [14C]aminopyrine accumulation in enzymatically dispersed enriched rat parietal cells [1].

Adrenocorticotropic Hormone (ACTH) (1-39), rat (TFA) is a potent melanocortin 2 receptor (MC2) agonist.

PACAP (1-38) free acid TFA, an endogenous neuropeptide, effectively enhances antral motility and somatostatin secretion, while concurrently suppressing gastrin secretion and promoting the release of vasoactive intestinal polypeptide, gastrin releasing peptide, and substance P. Additionally, it amplifies N-methyl-D-aspartate receptor function and brain-derived neurotrophic factor expression via RACK1 [1] [2].

Piscidin-1 (22-42) (TFA) is a highly potent, multi-functional Antimicrobial Peptide (AMP) produced by Orange-spotted grouper (Epinephelus coioides).

PD1-PDL1-IN 1 TFA (compound 16) is a potent inhibitor of programmed cell death 1 (PD-1), functioning as an immune modulator [1].

IGF-I (30-41) (TFA) is amino acids 30 to 41 fragment of Insulin-like Growth Factor I (IGF-I).

dTAGV-1 TFA is a highly effective and specific compound that targets mutant FKBP12 F36V fusion proteins for degradation. It possesses potent activity in inducing the degradation of the FKBP12 F36V -Nluc protein in living organisms.

Endogenous human tachykinin-like peptide and potent agonist for NK1 receptors (EC50 = 1 nM).

Klotho-derived peptide 1 (KP1) (56-87), a peptide originating from the human Klotho protein, disrupts TGF-β signaling by binding to TGF-β receptor types 1 and 2 (TGFBR1 and TGFBR2; Kds = 1.41 and 14.6 µM, respectively). Preincubation with KP1 at a concentration of 10 µg/ml hinders the TGF-β-induced escalation of fibronectin and α-smooth muscle actin (α-SMA) levels in NRK-49F rat fibroblasts. Furthermore, in vivo studies reveal that KP1, administered at 1 mg/kg per day, preferentially accumulates in damaged kidneys, leading to significant reductions in serum creatinine and blood urea nitrogen levels, indicators of improved kidney function. Additionally, it decreases kidney fibrosis in mouse models of unilateral ureteral obstruction (UUO) and unilateral ischemia-reperfusion injury-induced renal fibrosis.

TAT-DEF-Elk-1 TFA (TDE TFA) is a cell-penetrating peptide that inhibits Elk-1 by mimicking its DEF domain and disrupting its function. It effectively blocks Elk-1 phosphorylation and its subsequent nuclear translocation, without affecting the activation of ERK or MSK1. This compound serves as a valuable tool for investigating Elk-1's involvement in the development of neuronal plasticity [1].

HIF-1 alpha (556-574) TFA is a 19-residue fragment of hypoxia-inducible factor-1 (HIF-1), which serves as the master regulator of oxygen homeostasis [1].

Glucocorticoid Receptor Agonist-1 Phosphate Gly-Glu (TFA) serves as a cleavable linker for the synthesis of Antibody-Drug Conjugates (ADCs).

Notch 1 TFA encodes a member of the NOTCH family of proteins.

Proteasome-activating peptide 1 TFA is a potent activator of the proteasome, enhancing chymotrypsin-like proteasomal catalytic activity and thereby increasing proteolytic rates both in vitro and in culture. Additionally, it inhibits protein aggregation in cellular models of amyotrophic lateral sclerosis (ALS) [1].

Dynorphin A (1-10) (TFA), an endogenous opioid neuropeptide, binds in the transmembrane domain of the κ-receptor.

GIP (1-30) amide (Human) TFA is a glucose-dependent insulinotropic polypeptide fragment. Glucose-dependent insulinotropic polypeptide (GIP) is an incretin hormone that stimulates insulin secretion and reduces postprandial glycaemic excursions.

Protein Kinase C (19-31) TFA, a peptide inhibitor of protein kinase C (PKC), derived from the pseudo-substrate regulatory domain of PKCa (residues 19-31) with a serine at position 25 replacing the wild-type alanine, is used as protein kinase C substrate p

NEP(1-40) TFA is a peptide antagonist of the Nogo-66 receptor (NgR), which mitigates the shift in microglial morphology distributions due to injury by attenuating myelin-derived inhibition [1].

Orexin B, human (TFA) is an endogenous agonist at Orexin receptor with Kis of 420 and 36 nM for OX1 and OX2.

TAT TFA (YGRKKRRQRRR) is derived from human immunodeficiency virus (hiv-1) transcription reverse activator TAT, is a cell penetrating peptide.

HPV16 E7 (86-93) TFA is a human leukocyte antigen (HLA)-A2.1 restricted HPV16 E7-derived peptide.

Parathyroid Hormone (1-34), bovine TFA, a potent agonist of the parathyroid hormone (PTH) receptor, elevates calcium and inorganic phosphate levels in vivo. This compound is employed in osteoporosis research [1].

Dynorphin B (1-13), a 13 amino acid, is an extraordinarily potent opioid peptide.

FSL-1 TFA, a toll-like receptor 2/6 (TLR2/6) agonist derived from bacteria, bolsters resistance against experimental HSV-2 infection[1] and stimulates MMP-9 production via the TLR2 and NF-κB/AP-1 signaling pathways in monocytic THP-1 cells[2].

αvβ1 integrin-IN-1 TFA is an effective and selective αvβ1 integrin inhibitor (IC50: 0.63 nM).

Acts as a cardiac hormone with a variety of biological actions including natriuresis, diuresis, vasorelaxation, and inhibition of renin and aldosterone secretion. It is thought to play a key role in cardiovascular homeostasis. Helps restore the body\'s sa

PD-1-IN-17 TFA is a potent inhibitor of programmed cell death-1 (PD-1), inhibiting 92% of splenocyte proliferation at a concentration of 100 nM.

Magainin 1 TFA is an antimicrobial amphiphilic peptide isolated from xenopus skin.

αvβ1 Integrin-IN-1 TFA (Compound C8) is a potent, selective inhibitor of αvβ1 integrin, demonstrating an IC 50 value of 0.63 nM. It exhibits antifibrotic effects [1].

Hemokinin 1, human TFA acts as a selective full agonist at the tachykinin neurokinin 1 (NK1) receptor, while also being a full agonist at NK2 and NK3 receptors. It is capable of inducing opioid-independent analgesia [1] [2].

[Nphe1]Nociceptin(1-13)NH2 is a novel endogenous ligand for the nociceptin/orphanin FQ (NC) receptor, acting as a selective and competitive antagonist without any agonist effects. It binds specifically to recombinant nociceptin receptors with high affinity (pKi=8.4) and effectively blocks nociceptin's ability to inhibit cyclic AMP accumulation in CHO cells (pA2=6.0), showcasing potential as an analgesic agent.

Dynorphin B (1-13) TFA acts as an agonist on opioid κ-receptor .

β-Amyloid (1-43)(human) TFA exhibits greater aggregation tendencies and heightened toxicity compared to its well-established counterpart, Aβ1-42. Additionally, this compound demonstrates associations with both sAPPα and sAPPβ. It has the potential to serve as an additional biomarker for Alzheimer’s disease (AD), complementing existing markers [1].

ACTH (1-14) (TFA) is a regulatory fragment of adrenocorticotropin, specifically involved in the control of cortisol and androgen synthesis [1].

Super-TDU (1-31) TFA, a peptide fragment of Super-TDU, acts as an inhibitor of the YAP-TEAD complex. Demonstrating potent anti-tumor activity, it effectively suppresses tumor growth in a gastric cancer mouse model [1] [2].

TPP-1 TFA, a potent inhibitor of the PD-1/PD-L1 interaction, selectively binds to PD-L1 with high affinity (K D =95 nM). It effectively inhibits human tumor growth in vivo by reactivating T-cell function [1].

Defensin HNP-1 Human TFA, a human neutrophil peptide (HNP), plays a role in the early development of atherosclerosis by contributing to endothelial cell dysfunction. Additionally, it has demonstrated broad-spectrum antimicrobial and anti-leishmanial effects [1] [2].